Cancer 2019-09-15
Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Abstract
Background
The objective of this study was to evaluate local control for patients with intermediate-risk rhabdomyosarcoma (RMS) treated on Children's Oncology Group (COG) protocol ARST0531.
Methods
This study analyzed 424 patients with intermediate-risk RMS. Patients were randomized to chemotherapy with either vincristine, dactinomycin, and cyclophosphamide (VAC) or VAC alternating with vincristine and irinotecan. With the goal of improving local control, radiation therapy (RT) was delivered early at week 4 and was concurrent with irinotecan in the experimental arm. Individualized local control plans for children 24 months old or younger were allowed. Local failure on ARST0531 was compared with local failure on the preceding COG intermediate-risk study, D9803.
Results
For patients with group I/II alveolar RMS (n = 55), the 5-year cumulative incidence of local failure was 13.4%; for group III alveolar RMS (n = 141), it was 20.2%; and for group III embryonal RMS (n = 228), it was 27.9% (P = .03). Among patients with group III disease, local failure did not differ by histology, site, nodal status, RT modality, or treatment arm. Local failure was worse for a tumor size >5 cm (32.3% vs 16.7%; P = .001). Among patients with group III embryonal RMS, local failure was higher on ARST0531 than D9803 (27.9% vs 19.4%; P = .03). After the exclusion of patients 24 months old or younger or patients who did not receive radiation, local failure remained significantly increased on ARST0531 (P = .02). After adjustments for clinical prognostic factors, event-free survival and overall survival were worse on ARST0531 (P = .004 and P = .05, respectively).
Conclusions
Despite interventions designed to enhance local control, local control was inferior on ARST0531 in comparison with D9803. The reason for this is unclear, but it could be the reduced cyclophosphamide dose on ARST0531.
Related Questions
Would you recommend radiation therapy for an adult patient with rhabdomyosarcoma (embryonal) of the upper extremity s/p amputation with multiple lymph node involvement and ENE on pathology?
Yes, I would treat the involved nodal region. This patient has what appears to be stage III, group 2c intermediate-risk disease. If treating per ARST0531 dose to involved nodal region would be 41.4 Gy in 1.8 Gy per fraction, though with ENE, I would consider escalating that specific area to 50.4 Gy ...
What is your follow up schedule after completion of RT for pediatric rhabdomyosarcoma?
Imaging surveillance is an interesting and yet complicated issue. If a child is enrolled upon a prospective randomized trial for which informed consent has been given, then every effort should be made to follow the protocol guidelines, which are designed to answer a protocol question. However, patie...
What is the appropriate radiation volume for a stage III, group III unresectable embryonal rhabdomyosarcoma originating from the bladder?
For bladder/prostate or pelvic tumors that displaced a significant amount of bowel which has then returned to its normal anatomic position after chemotherapy, GTV1 and CTV1 will be defined by the prechemotherapy extent of tumor excluding the component that is now normal intra-abdominal components (i...
How should young patients with rhabdomyosarcoma be managed in the absence of a clinical trial?
The guiding principles of disease control while maintaining form, function, and quality of life drive the decision-making and management for patients with rhabdomyosarcoma.Regarding patients with paratesticular primary, inguinal orchiectomy with no scrotal invasion but tumor on the surface of the re...